← Charles River Laboratories overview

Charles River Laboratories vs Agilent: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Charles River Laboratories (CRL)

Q3 2026
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

July 2026
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

Latest
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

Agilent Technologies Inc (A)

Q3 2026
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

August 2026
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Latest
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

June 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

© 2026 MarketDXWhy